In articles published between 2012 and 2014, nilotinib had been shown to reduce alpha-synuclein levels in protein aggregation models of PD in rodents and to prevent the loss of dopaminergic neurons in a transgenic PD mouse model. This evidence concerns the gene SNCA and Parkinson disease.